Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit

This article was originally published in The Pink Sheet Daily

Executive Summary

Defendants in infringement case claim AstraZeneca Pharmaceuticals LP has no rights to the patent at issue.

You may also be interested in...



AstraZeneca Mulls Appeal After Australian Federal Court Rules Crestor Patents Invalid

AstraZeneca mulls an appeal of an Australian Federal Court judge’s ruling on Crestor patents as the anti-cholesterol drug faces a patent cliff worldwide.

Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)

TOKYO - Offering a mixed bag of earnings results, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe all await action of some sort by subsidiaries to determine their FY2010 outcomes. For Shionogi, that means a need for a U.S. rebound from its Sciele subsdiary, Daiichi Sankyo is holding out for the results of Ranbaxy, and Mitsubishi Tanabe is eyeing the impact of its subsidiary-induced sales suspension. [Editor's note: Part 1 of the Japanese earnings roundup with Astellas and Eisai appeared yesterday (PharmAsia New, Aug. 3, 2010).]

Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch

Switching statins OTC will require comprehensive consumer education to enable self-selection and flexibility from FDA on the types of information it considers product labeling

Related Content

Topics

UsernamePublicRestriction

Register

PS070309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel